SO-27 Efficacy and response rates of the RENCA Macrobead therapy (RMB): A novel approach to the treatment of metastatic colorectal cancer. phase II clinical trials [U.S. FDA BB-IND 10091]

2020 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []